Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,526,628
  • Shares Outstanding, K 54,974
  • Annual Sales, $ 607,520 K
  • Annual Income, $ 1,320 K
  • 60-Month Beta 1.01
  • Price/Sales 2.52
  • Price/Cash Flow 18.15
  • Price/Book 1.70
Trade SUPN with:

Options Overview Details

View History
  • Implied Volatility 43.28% ( +1.02%)
  • Historical Volatility 32.38%
  • IV Percentile 44%
  • IV Rank 56.94%
  • IV High 68.56% on 04/25/24
  • IV Low 9.83% on 08/18/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 53
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 2,275
  • Open Int (30-Day) 2,385

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.25
  • Number of Estimates 2
  • High Estimate 0.30
  • Low Estimate 0.21
  • Prior Year -0.02
  • Growth Rate Est. (year over year) +1,350.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.52 +0.91%
on 05/23/24
32.87 -15.52%
on 05/09/24
-2.18 (-7.28%)
since 04/23/24
3-Month
26.27 +5.70%
on 02/28/24
35.44 -21.64%
on 03/21/24
-1.29 (-4.44%)
since 02/23/24
52-Week
21.99 +26.28%
on 10/27/23
35.96 -22.78%
on 06/08/23
-6.29 (-18.47%)
since 05/23/23

Most Recent Stories

More News
Supernus: Q4 Earnings Snapshot

Supernus: Q4 Earnings Snapshot

SUPN : 27.77 (-0.36%)
Supernus: Q3 Earnings Snapshot

Supernus: Q3 Earnings Snapshot

SUPN : 27.77 (-0.36%)
Supernus: Q2 Earnings Snapshot

Supernus: Q2 Earnings Snapshot

SUPN : 27.77 (-0.36%)
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy

Supernus Pharmaceuticals' revenue mix is shifting, and it could soon have more sales on the way.

SUPN : 27.77 (-0.36%)
Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates...

SUPN : 27.77 (-0.36%)
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates

Supernus (SUPN) delivered earnings and revenue surprises of 141.67% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SUPN : 27.77 (-0.36%)
MYO : 3.83 (-5.67%)
Supernus: Q1 Earnings Snapshot

Supernus: Q1 Earnings Snapshot

SUPN : 27.77 (-0.36%)
BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -9.52% and 74.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BBIO : 27.76 (-5.16%)
SUPN : 27.77 (-0.36%)
Supernus Pharmaceuticals (SUPN) Q4 Earnings and Revenues Lag Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -41.10% and 8.15%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SUPN : 27.77 (-0.36%)
FIXX : 16.8246 (+0.77%)
Supernus: Q4 Earnings Snapshot

Supernus: Q4 Earnings Snapshot

SUPN : 27.77 (-0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit...

See More

Key Turning Points

3rd Resistance Point 29.85
2nd Resistance Point 29.33
1st Resistance Point 28.55
Last Price 27.77
1st Support Level 27.26
2nd Support Level 26.74
3rd Support Level 25.96

See More

52-Week High 35.96
Fibonacci 61.8% 30.62
Fibonacci 50% 28.97
Last Price 27.77
Fibonacci 38.2% 27.33
52-Week Low 21.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar